Loading news...
Medline Inc. (MDLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Wall Street has struck an early constructive tone on Medline Inc. (MDLN) following its $7.2 billion initial public offering last month, helping push the shares
Several analysts initiated coverage on Medline Inc. (NASDAQ: MDLN) on Monday, one of the largest providers of medical-surgical products and supply chain solutions.
Pre-Market Stock Futures: The futures are trading lower on Monday morning after a strong finish to the week on Friday, completing a winning week for investors as all three of the major indices closed at all-time highs. The news that Jay Powell, the Chairman of the Federal Reserve, is under criminal investigation by the Department... Here Are Monday's Top Wall Street Analyst Research Calls: Airbnb, Akamai, Applied Materials, CoreWeave, CrowdStrike, Datadog, NetFlix, Snowflake, and More.
Brokerages began coverage of Medline with largely bullish ratings on Monday, betting on supply chain strength and brand penetration, following the firm's upsized U.S. initial public offering in December - the biggest globally in 2025.
Vyome (NASDAQ: HIND - Get Free Report) and Medline (NASDAQ: MDLN - Get Free Report) are both manufacturing companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability. Earnings and Valuation This table compares Vyome and Medline"s gross
Last week's large-cap laggards were led by Regencell, AppLovin, and Palantir after big prior runs, while Tesla slipped on Q4 deliveries missing estimates amid Europe pressure, with additional downside across SailPoint, Carvana, Guidewire, QXO, Harmony Gold, and Medline.
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers and looks at catalysts that could be driving the attention.
NORTHFIELD, Ill., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that Jim Boyle, Chief Executive Officer, and Mike Drazin, Chief Financial Officer, are scheduled to present at the J.P. Morgan Healthcare Conference in San Francisco, Calif., on Tuesday, January 13, 2026, at 3:00 pm Pacific Time.
As the year winds down, many investors are positioning themselves for 2026 and beyond.
Stock News Paramount ups WBD bid financing: Paramount Skydance (PSKY) said Larry Ellison will personally guarantee $40.4B of equity for its $30/share all-cash h
Two sizable IPOs priced this week, joined by seven SPACs. Ten IPOs and eight SPACs submitted initial filings. No IPOs are currently scheduled in the week ahead, although smaller issuers may join the calendar throughout the week.
Medtronic's (NYSE: MDT) diabetes unit, MiniMed Group, filed for a U.S. initial public offering (IPO) on Friday.
Here are some of the major companies whose stocks moved on the week's news.
NORTHFIELD, Ill., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that it has closed its upsized initial public offering of 248,439,654 shares of its Class A common stock at a public offering price of $29.00 per share, including the full exercise by the underwriters of their option to purchase up to an additional 32,405,172 shares of Class A common stock.
Medline Inc. completed a record-setting $6.26B IPO, allocating proceeds primarily to reduce leveraged buyout debt from 2021. MDLN operates globally with $20.6B YTD revenue, stable 10% growth, and robust margins, though net income was previously pressured by high interest expense. Post-IPO, debt drops from $16.8B to ~$11B, significantly lowering interest burden and freeing up cash flow for operations and shareholder returns.
President Donald Trump defended the U.S. economy and blamed his predecessor. "I inherited a mess," he said.
Stock News Powerball jackpot nears record: Disney (DIS) network reports the Powerball jackpot has risen to an estimated $1.5 billion for Saturday after no winne
Medline completed a highly successful IPO, now trading at a $83 billion valuation, being granted a demanding 39x earnings multiple. Medline generates $25.5 billion in annual revenue, up 10% year-over-year, with adjusted EBITDA around $3.8 billion and net debt near $11 billion. Valuation is a key concern as private equity acquired the business at $34 billion just four years ago, raising questions about current pricing.
'Mad Money' host Jim Cramer breaks down Medline's IPO.